Low Vitamin D Status at Admission as a Risk Factor for Poor Survival in Hospitalized Patients With COVID-19: An Italian Retrospective Study.


Journal

Journal of the American Nutrition Association
ISSN: 2769-707X
Titre abrégé: J Am Nutr Assoc
Pays: United States
ID NLM: 9918300687506676

Informations de publication

Date de publication:
Historique:
pubmed: 19 2 2021
medline: 10 5 2022
entrez: 18 2 2021
Statut: ppublish

Résumé

Preliminary findings suggest a relationship between lower serum 25-hydroxyvitamin D [25(OH)D] levels and incidence and severity of COVID-19. The aim of this study was to evaluate the relationship between vitamin D status at admission and different markers of inflammation, coagulation, and sepsis in hospitalized patients with COVID-19. We conducted a retrospective study on 137 consecutive patients with SARS-CoV-2 infection and available data on serum 25(OH)D levels, who were admitted to our Institution between March 1 and April 30, 2020. Patients were divided into two groups: survivors (n = 78; 57%) and non-survivors (n = 59; 43%). At admission, all patients showed hypovitaminosis D. Median total serum 25(OH)D levels at admission were significantly higher in survivors than non-survivors (12 ng/mL vs 8 ng/mL; We found a markedly high prevalence (100%) of hypovitaminosis D in patients admitted to hospital with COVID-19, suggesting a possible role of low vitamin D status in increasing the risk of SARS-CoV-2 infection and subsequent hospitalization. The inverse association between serum 25(OH)D levels and risk of in-hospital mortality observed in our cohort suggests that a lower vitamin D status upon admission may represent a modifiable and independent risk factor for poor prognosis in COVID-19.

Identifiants

pubmed: 33600292
doi: 10.1080/07315724.2021.1877580
pmc: PMC7899172
doi:

Substances chimiques

Biomarkers 0
Interleukin-6 0
Procalcitonin 0
Vitamins 0
Vitamin D 1406-16-2
C-Reactive Protein 9007-41-4
Ferritins 9007-73-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

250-265

Auteurs

Marco Infante (M)

Department of Systems Medicine, Diabetes Research Institute Federation (DRIF), CTO Hospital ASL Roma 2, University of Rome Tor Vergata, Rome, Italy.
UniCamillus, Saint Camillus International University of Health Sciences, Rome, Italy.
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Rome, Italy.

Andrea Buoso (A)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Infectious Disease Clinic, Tor Vergata University Hospital (PTV), Rome, Italy.

Massimo Pieri (M)

Clinical Biochemistry and Molecular Biology, Department of Experimental Medicine, Faculty of Medicine, University of Rome Tor Vergata, Rome, Italy.
Clinical Biochemistry Department, Tor Vergata University Hospital (PTV), Rome, Italy.

Santina Lupisella (S)

Clinical Biochemistry and Molecular Biology, Department of Experimental Medicine, Faculty of Medicine, University of Rome Tor Vergata, Rome, Italy.

Marzia Nuccetelli (M)

Clinical Biochemistry and Molecular Biology, Department of Experimental Medicine, Faculty of Medicine, University of Rome Tor Vergata, Rome, Italy.

Sergio Bernardini (S)

Clinical Biochemistry and Molecular Biology, Department of Experimental Medicine, Faculty of Medicine, University of Rome Tor Vergata, Rome, Italy.
Clinical Biochemistry Department, Tor Vergata University Hospital (PTV), Rome, Italy.

Andrea Fabbri (A)

Department of Systems Medicine, Diabetes Research Institute Federation (DRIF), CTO Hospital ASL Roma 2, University of Rome Tor Vergata, Rome, Italy.

Marco Iannetta (M)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Infectious Disease Clinic, Tor Vergata University Hospital (PTV), Rome, Italy.

Massimo Andreoni (M)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Infectious Disease Clinic, Tor Vergata University Hospital (PTV), Rome, Italy.

Vittorio Colizzi (V)

UNESCO Chair of Biotechnology & Bioethics, University of Rome Tor Vergata, Rome, Italy.

Maria Morello (M)

Clinical Biochemistry and Molecular Biology, Department of Experimental Medicine, Faculty of Medicine, University of Rome Tor Vergata, Rome, Italy.
Clinical Biochemistry Department, Tor Vergata University Hospital (PTV), Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH